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This adjunct medication  
can speed CAP recovery
Adding prednisone to the antibiotic regimen can 
help patients hospitalized with community-acquired 
pneumonia to stabilize more quickly and leave the 
hospital sooner.  
PRACTICE CHANGER 
Prescribe oral prednisone 50 mg/d to hospi-
talized patients with mild to moderate com-
munity-acquired pneumonia. It decreases 
time to clinical stability and length of hospi-
tal stay.1
StreNGtH oF reCoMMeNDAtioN 
A: Based on a single good-quality random-
ized controlled trial and meta-analysis.
Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for pa-
tients with community-acquired pneumonia: a multicentre, double-
blind, randomized, placebo-controlled trial. Lancet. 2015;385:1511-
1518.
ILLUSTRATIVE CASE
a 75-year-old woman with hypertension and 
diabetes mellitus presents to the emergency 
department with shortness of breath, cough, 
and fever that she’s had for 4 days. on exami-
nation, her temperature is 38.2°c (100.7°f), 
heart rate is 110 beats/min, respiratory rate 
is 28 breaths/min, oxygen saturation is 91%, 
and rhonchi are heard in her right lower lung 
field. a chest x-ray reveals an infiltrate in her 
right lower lobe. The patient is admitted and 
started on intravenous (iV) antibiotics, iV flu-
ids, acetaminophen for fever, and oxygen. can 
anything else be done to speed her recovery?
Community-acquired pneumonia (CAP) is responsible for more than one million hospitalizations annually in the United 
States, and is the 8th leading cause of death.2,3 
Treatment of CAP typically consists of antibiotics 
and supportive measures such as IV fluids and 
antipyretics. Because the disease process of CAP 
involves extensive inflammation, adjunct treat-
ment with corticosteroids may be beneficial. 
Multiple studies have shown that treat-
ment with corticosteroids can help patients 
with severe CAP, but the potential benefit in 
patients with less severe CAP has been un-
certain.4,5 A Cochrane systematic review pub-
lished in 2011 identified 6 small randomized 
controlled trials (RCTs) that evaluated the im-
pact of corticosteroids on recovery from CAP.4 
It suggested that corticosteroids may decrease 
time to recovery, but the studies that included 
patients with less severe CAP had a relatively 
high risk of bias. 
Subsequently, a 2012 meta-analysis of 
9 RCTs explored whether corticosteroids af-
fected mortality in CAP; no benefit was ob-
served in patients with less severe CAP.5 Most 
recently, a 2013 meta-analysis of 8 moderate-
quality RCTs showed that corticosteroid use 
was associated with shorter hospital stays, but 
no change in mortality.6
The synthesis of small or moderate-
quality studies suggests some potential 
benefit in treating less severe CAP with cor-
ticosteroids, but there has been a need for a 
large, definitive, high-quality RCT. This study 
investigated the impact of a short course of 
oral steroids on inpatients with less severe 
CAP. 
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STUDY SUMMARY
Prednisone hastens clinical stabilization, 
cuts length of hospital stay
In a multicenter, double-blind RCT, Blum 
et al1 enrolled 785 patients with CAP admit-
ted to 7 tertiary care hospitals in Switzerland 
from 2009 to 2014. Patients were eligible for 
the study if they were ≥18 years old, had a 
new infiltrate on chest x-ray, and had at least 
one additional sign or symptom of respira-
tory illness (eg, cough, dyspnea, fever, abnor-
mal breathing signs or rales, or elevated or 
decreased white blood cell count). Patients 
were excluded if they had one of several pos-
sible contraindications to corticosteroids, 
cystic fibrosis, or active tuberculosis.
Patients were randomized to receive ei-
ther prednisone 50 mg/d or placebo for 7 days. 
They were treated with antibiotics according 
to accepted local guidelines; most patients 
received either amoxicillin/clavulanic acid or 
ceftriaxone. Antibiotic treatment was adjusted 
according to susceptibility whenever a specific 
pathogen was identified. Nurses assessed all 
patients every 12 hours during hospitalization, 
and laboratory tests were obtained on hospi-
tal Days 1, 3, 5, and 7, and before discharge. 
Follow -up telephone interviews were con-
ducted on Day 30. 
The primary outcome was length of time 
to clinical stability, which was defined as at 
least 24 hours of stable vital signs. Stable vital 
signs was a composite endpoint that required 
all of the following: temperature ≤37.8°C 
(≤100°F), heart rate ≤100 beats/min, sponta-
neous respiratory rate ≤24 breaths/min, sys-
tolic blood pressure ≥90 mm Hg (≥100 mm 
Hg for patients diagnosed with hypertension) 
without vasopressor support, mental status 
back to baseline, ability to take food by mouth, 
and adequate oxygenation on room air. 
Secondary outcomes included length of 
hospital stay, pneumonia recurrence, hospital 
readmission, intensive care unit (ICU) admis-
sion, all-cause mortality, and duration of an-
tibiotic treatment. Researchers also explored 
whether the rates of complications from 
pneumonia or corticosteroid use differed be-
tween the prednisone and placebo groups.
In an intention-to-treat analysis, the me-
dian time to clinical stability was shorter for 
the prednisone group at 3 days (interquartile 
range [IQR]=2.5-3.4) compared to the pla-
cebo group at 4.4 days (IQR=4-5; hazard ra-
tio [HR]=1.33; 95% confidence interval [CI], 
1.15-1.50; P<.0001). Median time to hospital 
discharge was also shorter for the predni-
sone group (6 days vs 7 days; HR=1.19; 95% 
CI, 1.04-1.38; P=.012) as was duration of IV 
antibiotic treatment (4 days vs 5 days, dif-
ference=-0.89 days; 95% CI, -1.57 to -0.20; 
P=.011). 
There were no statistically significant dif-
ferences in pneumonia recurrence, hospital 
readmission, ICU admission, or all-cause 
mortality. Patients treated with prednisone 
were more likely to experience hyperglyce-
mia that required insulin treatment during 
admission (19% vs 11%; odds ratio=1.96; 95% 
CI, 1.31-2.93; P=.001). 
WHAT’S NEW
this large, good-quality study   
reinforces previous evidence
This is the largest good-quality RCT to explore 
the impact of corticosteroid treatment on less 
severe CAP. Previous studies suggested that 
corticosteroids may decrease the duration of 
illness, but this is the first rigorous study to 
show a clear decrease in both time to clinical 
stability and length of hospital stay. 
Also, this study used an easy-to-ad-
minister dose of oral steroids, instead of the 
several -day course of IV steroids used in most 
other studies. The findings from this study 
were incorporated into a 2015 meta-analysis 
that confirmed that corticosteroid treatment 
in patients with less severe CAP results in a 
shorter length of hospital stay and decreased 
time to clinical stability.7
CAVEATS
it’s unclear whether steroids can benefit 
nonhospitalized patients 
Because this study included hospitalized pa-
tients only, it’s not clear whether corticoste-
roids have a role in outpatient treatment of 
CAP. Additionally, while this was a large, well-
performed study, it did not have a sufficient 
number of patients to examine whether cor-
ticosteroids impact mortality among patients 
with CAP. Finally, the average length of hos-
the median 
time to clinical 
stability was 
shorter for the 
prednisone 
group (3 days) 
than for the  
placebo group 
(4.4 days).
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pital stay reported in this study was approxi-
mately 1.5 days longer than the typical length 
of stay in the United States.2 The average length 
of stay has varied widely in studies examining 
corticosteroids in CAP, but good-quality stud-
ies have consistently shown a median reduc-
tion in length of stay of one day.7 
CHALLENGES TO IMPLEMENTATION
Steroids carry a risk of adverse events, 
including hyperglycemia
Treatment with prednisone increases the risk 
of corticosteroid-related adverse events, pri-
marily hyperglycemia and the need for insu-
lin. This may not be well received by patients 
or providers. However, these adverse effects 
appear to resolve quickly after treatment, 
and do not impact the overall time to clinical 
stability.                  JFP
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